Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation

• Molecular testing may play a role in the determination of targeted therapy treatment options. • Targeted therapy provides treatment options for recurrent cervical cancer. • MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.

Detalles Bibliográficos
Autores principales: Lyons, Yasmin A., Frumovitz, Michael, Soliman, Pamela T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434143/
https://www.ncbi.nlm.nih.gov/pubmed/26075998
http://dx.doi.org/10.1016/j.gore.2014.09.003
_version_ 1782371733853962240
author Lyons, Yasmin A.
Frumovitz, Michael
Soliman, Pamela T.
author_facet Lyons, Yasmin A.
Frumovitz, Michael
Soliman, Pamela T.
author_sort Lyons, Yasmin A.
collection PubMed
description • Molecular testing may play a role in the determination of targeted therapy treatment options. • Targeted therapy provides treatment options for recurrent cervical cancer. • MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation.
format Online
Article
Text
id pubmed-4434143
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-44341432015-06-05 Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation Lyons, Yasmin A. Frumovitz, Michael Soliman, Pamela T. Gynecol Oncol Rep Short Communication • Molecular testing may play a role in the determination of targeted therapy treatment options. • Targeted therapy provides treatment options for recurrent cervical cancer. • MEK inhibitor is a treatment option for recurrent cervical cancer in a patient with KRAS mutation. Elsevier 2014-10-25 /pmc/articles/PMC4434143/ /pubmed/26075998 http://dx.doi.org/10.1016/j.gore.2014.09.003 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
spellingShingle Short Communication
Lyons, Yasmin A.
Frumovitz, Michael
Soliman, Pamela T.
Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
title Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
title_full Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
title_fullStr Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
title_full_unstemmed Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
title_short Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation
title_sort response to mek inhibitor in small cell neuroendocrine carcinoma of the cervix with a kras mutation
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434143/
https://www.ncbi.nlm.nih.gov/pubmed/26075998
http://dx.doi.org/10.1016/j.gore.2014.09.003
work_keys_str_mv AT lyonsyasmina responsetomekinhibitorinsmallcellneuroendocrinecarcinomaofthecervixwithakrasmutation
AT frumovitzmichael responsetomekinhibitorinsmallcellneuroendocrinecarcinomaofthecervixwithakrasmutation
AT solimanpamelat responsetomekinhibitorinsmallcellneuroendocrinecarcinomaofthecervixwithakrasmutation

Ejemplares similares